Literature DB >> 29249529

Optimal High-Dose-Rate Brachytherapy Fractionation Scheme After Keloid Excision: A Retrospective Multicenter Comparison of Recurrence Rates and Complications.

Eveline Bijlard1, Gerda M Verduijn2, J X Harmeling3, Homan Dehnad4, Frank B Niessen5, Otto W M Meijer6, Marc A M Mureau3.   

Abstract

PURPOSE: To determine the optimal brachytherapy dose and fractionation scheme for keloid treatment. METHODS AND MATERIALS: Patient cohorts from 3 centers treated with keloid excision followed by 2 × 9 Gy, 3 × 6 Gy, or 2 × 6 Gy high-dose-rate brachytherapy were retrospectively compared regarding recurrence (after at least 12 months' follow-up) and complications (after at least 1 month's follow-up), using logistic regression analyses.
RESULTS: A total of 238 keloids were treated. An overall full recurrence rate of 8.3% was found. After correction for confounders (sex, skin color, keloid location, keloid duration) no statistically significant differences in recurrence rates could be discerned between fractionation schemes. There were 12.8% major and 45.6% minor complication rates. Lower radiation dose resulted in significantly fewer complications (odds ratio 0.35, P=.015).
CONCLUSIONS: After excision of resistant keloids, high-dose-rate brachytherapy with a biological equivalent dose of approximately 20 Gy is recommended, on the basis of low recurrence and complication rates.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29249529     DOI: 10.1016/j.ijrobp.2017.10.044

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

Review 1.  Adjuvant Radiotherapy for Keloids.

Authors:  Wenfang Dong; Bin Qiu; Fei Fan
Journal:  Aesthetic Plast Surg       Date:  2021-08-20       Impact factor: 2.326

2.  Feasibility of aponeurectomy in combination with perioperative 192Ir high dose rate brachytherapy for Dupuytren's disease.

Authors:  I Frank Ciernik; Philipp Goldschmidt; Markus Wösle; Jochen Winter
Journal:  Strahlenther Onkol       Date:  2021-09-07       Impact factor: 3.621

3.  Integrated Interaction Network of MicroRNA Target Genes in Keloid Scarring.

Authors:  Lechun Lyu; Yu Zhao; Hongquan Lu; Zijie Liu; Jiazhi Guo; Di Lu; Xiang Li
Journal:  Mol Diagn Ther       Date:  2019-02       Impact factor: 4.074

4.  Surface brachytherapy in the treatment of keloid scars in Mexico.

Authors:  Yicel Bautista Hernandez; Michelle Aline Villavicencio Queijero; Abril Antonia Quezada Bautista; Azcary Vazquez Tinajero
Journal:  Rep Pract Oncol Radiother       Date:  2019-12-24

5.  Subdermal injection of hyaluronic acid to decrease skin toxicity from radiation delivered with low-dose-rate brachytherapy for cancer patients.

Authors:  Yuan Yuan; Zhang Ying; Dai Jianjian; Lin Qi; Xu Ruicai; Geng Baocheng; Han Mingyong
Journal:  J Contemp Brachytherapy       Date:  2019-02-28

6.  Scoping Review of Therapeutic Strategies for Keloids and Hypertrophic Scars.

Authors:  Jaclyn B Anderson; Aaron Foglio; Alex B Harrant; Christene A Huang; C Scott Hultman; David W Mathes; Tae W Chong
Journal:  Plast Reconstr Surg Glob Open       Date:  2021-03-22

7.  Perioperative interstitial high-dose-rate brachytherapy for keloids scar.

Authors:  Victoria Vera Barragán; Ana Isabel Alonso García; José Fernández García; Marta De Juan Marín; Johanna Del Carmen Peña Vivas; Germán Juan Rijo
Journal:  J Contemp Brachytherapy       Date:  2022-02-18

8.  Silencing circular RNAPTPN12 promoted the growth of keloid fibroblasts by activating Wnt signaling pathway via targeting microRNA-21-5p.

Authors:  Fei Liu; Tao Li; Xiaoan Zhan
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.